Selected article for: "disease slow and time disease slow"
Author: Khater, Ibrahim; Nassar, Aaya
Title: In silico molecular docking analysis for repurposing approved antiviral drugs against SARS-CoV-2 main protease
  • Cord-id: 7v4au1ml
  • Document date: 2021_6_3
    • ID: 7v4au1ml
    Snippet: Developing a safe and effective antiviral treatment takes a decade, however, when it comes to the coronavirus disease (COVID-19), time is a sensitive matter to slow the spread of the pandemic. Screening approved antiviral drugs against COVID-19 would speed the process of finding therapeutic treatment. The current study examines commercially approved drugs to repurpose them against COVID-19 virus main protease using structure-based in-silico screening. The main protease of the coronavirus is esse
    Document: Developing a safe and effective antiviral treatment takes a decade, however, when it comes to the coronavirus disease (COVID-19), time is a sensitive matter to slow the spread of the pandemic. Screening approved antiviral drugs against COVID-19 would speed the process of finding therapeutic treatment. The current study examines commercially approved drugs to repurpose them against COVID-19 virus main protease using structure-based in-silico screening. The main protease of the coronavirus is essential in the viral replication and is involved in polyprotein cleavage and immune regulation, making it an effective target when developing the treatment. A Number of approved antiviral drugs were tested against COVID-19 virus using molecular docking analysis by calculating the free natural affinity of the binding ligand to the active site pocket and the catalytic residues without forcing the docking of the ligand to active site. COVID-19 virus protease solved structure (PDB ID: 6LU7) is targeted by repurposed drugs. The molecular docking analysis results have shown that the binding of Remdesivir and Mycophenolic acid acyl glucuronide with the protein drug target has optimal binding features supporting that Remdesivir and Mycophenolic acid acyl glucuronide can be used as potential anti-viral treatment against COVID-19 disease.

    Search related documents:
    Co phrase search for related documents
    • active form and acute respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • active form and acute respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • active sars site pocket and acute respiratory: 1
    • active sars site pocket and acute respiratory syndrome coronavirus: 1
    • active site and acute respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • active site and acute respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • active site bind and acute respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • active site bind and acute respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • active site dock and acute respiratory: 1
    • active site dock and acute respiratory syndrome coronavirus: 1
    • active site inhibitor and acute respiratory: 1, 2, 3, 4, 5, 6
    • active site inhibitor and acute respiratory syndrome coronavirus: 1, 2, 3, 4, 5
    • active site inhibitor binding and acute respiratory: 1, 2, 3
    • active site inhibitor binding and acute respiratory syndrome coronavirus: 1, 2, 3
    • active site pocket and acute respiratory: 1, 2, 3
    • active site pocket and acute respiratory syndrome coronavirus: 1, 2
    • acute respiratory and lymphopenia smell: 1
    • acute respiratory and lymphopenia smell taste: 1
    • acute respiratory syndrome coronavirus and lymphopenia smell taste: 1